Summary: Bio-Rad Labs introduced the Vericheck ddPCR Empty-Full Capsid Kit, designed to determine capsid titer, genome titer, and the percentage of full capsids in AAV samples.

Takeaways:

  1. The Vericheck ddPCR Empty-Full Capsid Kit utilizes Bio-Rad’s Droplet Digital PCR technology to deliver precise, reproducible data from minimal AAV samples, including crude lysate or purified samples.
  2. This cost-effective kit streamlines AAV vector characterization processes, helping optimize gene therapy production and ensuring compliance with regulatory standards.
  3. The kit addresses the challenge of detecting product impurities like partial or empty capsids, aiding the development of safer, more effective gene therapies.

Bio-Rad Labs announced the launch of the Vericheck ddPCR Empty-Full Capsid Kit for the determination of capsid titer, genome titer, and percentage of full capsids in purified or unpurified (crude lysate) AAV samples. 

Bio-Rad’s Capsid Kit

Using Bio-Rad’s Droplet Digital PCR technology, the new Vericheck ddPCR Empty-Full Capsid Kit analyzes minimal amounts of either crude lysate or purified samples to deliver robust, reproducible data for reliable assessment of AAV vector quality. 

Designed for use on Bio-Rad’s Droplet Digital PCR Systems, the kit’s solution enables optimization of AAV vector characterization processes to streamline gene therapy development and production while supporting compliance with regulatory guidelines. 

“AAV vectors are a powerful gene therapy tool, but their production can result in the generation of product-related impurities, such as partial or empty capsids, which impact effectiveness and can elicit unwanted immunotoxicity. Determining the ratio of full, partial, and empty capsids is a recurring challenge throughout AAV gene therapy manufacturing, from early-stage development to quality control and release testing,” says Stephen Kulisch, VP of marketing for Bio-Rad’s Digital Biology Group. “Our new Vericheck ddPCR Empty-Full Capsid Kit delivers unmatched precision and specificity, along with ease of use and high-throughput capabilities, to provide our customers with a comprehensive solution for AAV vector characterization and to help drive the advancement of safe and effective gene therapies.”

Photo: Bio-Rad